Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Anergis
company
About
Anergis discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization.
- 11 - 50
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- Fr8M
- Industries
- Biotechnology,Health Care,Life Science,Medical,Personal Health
- Founded date
- Jan 1, 2001
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
Fr27.50M
Anergis has raised a total of
Fr27.50M
in funding over 2 rounds. Their latest funding was raised on
Apr 4, 2016 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 4, 2016 | Series C | Fr5M | 1 | — | — | Detail |
| Dec 3, 2014 | Series B | Fr14.50M | 1 |
Renaissance
|
— | Detail |
| Feb 7, 2014 | Series A | Fr8M | 1 |
Renaissance
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
1
Anergis is funded by 1 investors.
Renaissance
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Renaissance
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
